发明名称 BQC-G, a tumor-selective anti-cancer prodrug
摘要 The invention relates to the synthesis of a second-generation camptothecin glucuronide prodrug (BQC-G) of a potent anticancer camptothecin derivative 5,6-dihydro-4H-benzo[de]quinoline-camptothecin (BQC). BQC-G was over 4000 times more water soluble than BQC, displayed good stability in human plasma and was an excellent substrate for enzymatic hydrolysis by bacterial and human β-glucuronidases. BQC-G was about 30 times less toxic than BQC, but was as toxic as BQC after hydrolysis of the glucuronide moiety by β-glucuronidase. In the presence of human serum albumin, BQC-G displayed lower cytotoxicity (IC50=1080 nM) but could be activated by β-glucuronidase to display potent activity (IC50=13.3 nM).
申请公布号 US9353140(B2) 申请公布日期 2016.05.31
申请号 US201013512255 申请日期 2010.11.24
申请人 Academia Sinica 发明人 Prijovic Zeljko M.;Leu Yu-Lin;Roffler Steve R.
分类号 A61K31/706;C07H15/26;A61P35/00;C07H15/203 主分类号 A61K31/706
代理机构 Drinker Biddle & Reath LLP 代理人 Drinker Biddle & Reath LLP
主权项 1. A compound according to the formula I, below: wherein R is a glucuronide linked via an immolative spacer, or a pharmaceutically acceptable salt thereof.
地址 Taipei TW